Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
brensocatib + rifampin
- Development stage
- Unknown
- Lead developer
- Insmed
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Brensocatib + rifampin is a combination of two drugs: brensocatib, a competitive, reversible small molecule inhibitor of dipeptidyl peptidase 1 (DPP1), and rifampin, a strong CYP3A4 inducer and antibiotic. Brensocatib acts by preventing activation of neutrophil serine proteases (NSPs) in neutrophil maturation, thereby reducing inflammation and tissue destruction in neutrophil-mediated diseases. Rifampin induces CYP3A4, leading to decreased plasma exposure of brensocatib when co-administered. This combination is not an approved therapy but has been studied pharmacokinetically for potential drug-drug interactions in research settings[1][3].
02
Targets
CTSC (DPP1)
Beyond the preview
Go deeper on brensocatib + rifampin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on brensocatib + rifampin.